| |
Justification: arterial hypertension (AH) is one of the most common diseases and the leading risk factor for coronary heart disease, myocardial infarction, stroke, vascular lesions, chronic kidney disease and premature death. The main objective of treatment of hypertension, according to modern strategies and results of multicenter studies, is to achieve the target blood PRESSURE level, ensuring the protective effect of antihypertensive agents on target organs, as well as the maximum reduction of the risk of cardiovascular complications and mortality.
Objective: to improve the efficiency of diagnosis and treatment of patients with stage II hypertension 2-3 degrees based on the study of daily blood PRESSURE monitoring, blood lipid spectrum, systemic inflammation and uric acid levels, correction of the detected disorders using lisinopril with amlodipine, bisoprolol with amlodipine and rosuvastatin with ravisol.
Results: according to our study, the use of rosuvastatin at a dose of 10 mg in patients with hypertension led to a significant decrease in SC by 20% (P0, 05). The most pronounced dynamics of the level of SC was observed in the group of patients who alternately received combined drugs. This indicates, obviously, evidence of the pleetropic ability to influence drugs such as lisinopril, amlodipine and rosuvastatin on the level of SC. When combined treatment of patients with Ah ravisol observed better dynamics of the level of SC in group I patients at 26.1% (P0, 01), II-23.6% (P0, 01), III-27.7% (P0, 01).
The results of our study found that the level of SC is associated with both SAD and DADAM. There is a relationship between the average daily PAO (r=0.39; p<0.05) and heart rate (r=0.51; p<0.05).
Conclusion: in the course of treatment with combined antihypertensive agents, there was a significant decrease in Smad indicators. The most effective treatment is in a group of patients who alternately received combined drugs
Keywords:антигипертензивная терапия, гипертоническая болезнь, рависол, артериальная гипертензия.
|
LEGAL
INFORMATION:
